Ambulatory Surgical Center Implantable Cardioverter-Defibrillator Outcomes Registry
Launched by QUESGEN SYSTEMS INC · Jul 18, 2018
Trial Information
Current as of April 28, 2025
Recruiting
Keywords
ClinConnect Summary
The Ambulatory Surgical Center Implantable Cardioverter-Defibrillator Outcomes Registry is a clinical trial that aims to understand how often serious complications occur when patients receive implantable cardioverter-defibrillators (ICDs) for heart rhythm problems, known as arrhythmias. The study will also look at how much time and money these procedures take for both doctors and patients. Participants will be monitored at three key points: when they are screened for the procedure, during the implant, and again two weeks later during a follow-up visit.
To join this study, a patient must have a doctor’s recommendation to receive an ICD in an Ambulatory Surgical Center, which is a facility that allows for outpatient procedures. There are no specific exclusions, so many patients with a recommendation may qualify. If eligible, participants can expect to help researchers gather important information that could improve future heart care while also receiving standard medical follow-up after their procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Physician recommendation to receive the implant in an Ambulatory Surgical Center (ASC)
- Exclusion Criteria:
- • N/A
About Quesgen Systems Inc
Quesgen Systems Inc. is a pioneering clinical trial sponsor specializing in the development and implementation of innovative software solutions for the healthcare and clinical research sectors. With a focus on enhancing data management and analysis, Quesgen empowers researchers and organizations to streamline their clinical trials, ensuring compliance with regulatory standards while improving efficiency and accuracy. Their commitment to advancing clinical research is underscored by a robust portfolio of user-friendly tools designed to facilitate real-time data collection and reporting, ultimately contributing to improved patient outcomes and accelerated drug development processes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lehi, Utah, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials